FDA 483 - Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company - September 11, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Bristol-Myers Squibb Holdings Pharma Ltd in Manati, Puerto Rico, identified significant deficiencies in data integrity and laboratory controls. The firm failed to adequately monitor and investigate electronic record issues from chromatographic systems, leading to unaddressed data loss or alteration. Additionally, laboratory investigations for drug products like Coumadin and Elotuzumab Injection were found to be scientifically unsound, and the firm did not thoroughly review unexplained discrepancies related to product testing and release.
- Inspection Date
- September 11, 2017
- Product Type
- Drugs
ID · 8e009935-5ba5-495d-8aa2-4f8de0e2e8ae